LTRN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Lantern Pharma Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.63 USD
-4.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -8.8% below the Trend Line and sits at 32.8% of its 52-week range. The latest completed week returned -4.4%, after a -33.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 9d.

Setup score 22 out of 100
Latest Close 2.63 USD 31 Jul 2026
1W Return -4.4% latest completed week
4W Return -33.8% short-term follow-through
12W Return 25.2% quarterly tape
Trend Breadth 28.8% 15 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.4% Latest completed week; four-week move -33.8%. Indicator stack 33/44 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 42/100 conviction; expected move 91.4%. News sentiment 57/100 58 relevant articles in the latest sentiment read. Event risk 9d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -8.8% below the Trend Line and sits at 32.8% of its 52-week range. The latest completed week returned -4.4%, after a -33.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6412-week average 0.33

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.64Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -33.8% over four weeks, 25.2% over 12 weeks, and -44.9% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W-4.4%
4W-33.8%
12W25.2%
26W-16.5%
52W-44.9%
Active trend streak5 weeks
Active weeks in one year15
Trend breadth28.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.10Latest activity-pressure read.
Pressure change-90.5%Four-week change in activity pressure.
Leadership-27.72Latest relative-leadership reading.
RS change-4840.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 60%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength54/100Blend of value, momentum, and quality. Underlying universe rank 47; rank 1 is best.
Value51/100Relative valuation strength. Underlying universe rank 50; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth51/100Revenue and earnings growth. Underlying universe rank 50; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-52.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-4.8%
Net share repurchases relative to market value.
Shareholder yield
-4.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

LTRN shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.81, expected move of 91.4%, and Sharemaestro trend signal active.

Conviction42/100
Expected move91.4%
Put/call volume0.81
Pressure20
Speculation24
Volatility96
Trend agreement72
Open options detail
Insider activity2 / 2

2 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 58 relevant articles.

16 positive · 41 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings9dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move91.4%Nearest-chain priced movement where available.
52-week drawdown-54.2%Distance below the 52-week high.
13-week volatility15.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2614 weeks finished lower.
Best week+49.5%Week of 15 May.
Worst week-47.4%Week of 27 Mar.
Latest week-4.4%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks1
Modest losses4
Sharp losses10
Recent vol15.5%13-week weekly-return volatility.
Base vol14.7%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew11.7% / -9.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis53/100

Latest 12-week confirmation: trend 5/12, activity pressure 12/12, relative leadership 1/12.

Activity pressure 0.64; No reversal markers Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 83 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options63/100

LTRN shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.81, expected move of 91.4%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 91.4% Sentiment57/100

Weighted news tone is neutral across 58 relevant articles.

Enterprise value to EBIT forward of Lantern Pharma Inc. – NASDAQ:LTRN Insiders2 / 2

2 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings9d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.63 USD-4.4%2.89 USD3.97 USD0.10-27.72265.5KOn
24 Jul 20262.75 USD-4.2%2.90 USD3.98 USD0.46-25.31382.4KOn
17 Jul 20262.87 USD-20.3%2.93 USD3.99 USD0.78-24.24760.4KOn
10 Jul 20263.60 USD-9.3%2.94 USD4.00 USD1.00-9.881.3MOn
3 Jul 20263.97 USD2.8%2.94 USD4.01 USD1.010.58544.9KOn
26 Jun 20263.86 USD1.8%2.93 USD4.02 USD1.01-1.46794.4KOff
19 Jun 20263.79 USD-2.3%2.92 USD4.03 USD1.02-7.72878.8KOff
12 Jun 20263.88 USD8.1%2.90 USD4.04 USD1.02-3.321.1MOff
5 Jun 20263.59 USD0.0%2.88 USD4.05 USD1.00-8.621.3MOff
29 May 20263.59 USD2.6%2.88 USD4.07 USD0.70-13.09812.9KOff
22 May 20263.50 USD11.5%2.89 USD4.07 USD0.34-13.131.5MOff
15 May 20263.14 USD49.5%2.91 USD4.08 USD0.02-21.553.0MOff
8 May 20262.10 USD-0.9%2.94 USD4.09 USD-0.35-48.05697.5KOff
1 May 20262.12 USD-13.8%3.01 USD4.11 USD-0.57-45.631.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.